In this context, authors found that the addition of the lipids’ lowering agents (PCSK9 inhibitor) to high-intensity statin therapy in patients with acute myocardial infarction, reducing the blood lipids values significantly, resulted in favorable effects on coronary atherosclerosis [28]. This evidence concerns the gene PCSK9 and myocardial infarction.